(Reuters) – Gilead Inc said on Friday the U.S. Food and Drug Administration has authorized expanded emergency use for its experimental antiviral COVID-19 treatment, remdesivir.
The drug can now be used to treat all hospitalized patients with COVID-19, in addition to patients with a severe form of the illness. (https://reut.rs/31DfMIk)
(Reporting By Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
